Compare GSK plc (GSK) vs InMode Ltd (INMD) Price & Performance

GSK's stock trades at $51.25, down 1.99% on the day, with a bearish technical signal from moving averages. Fundamentally, the company shows strong profitability with a 17.78% net margin and 36.42% ROE, supported by a consistent earnings beat history. Recent positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline progress. Valuation appears reasonable with a P/E of 13.71 and EV/EBITDA of 9.16.

The outlook balances a solid core business and promising oncology pipeline against a mixed analyst consensus and near-term cash flow pressures. Key opportunities lie in execution of new drug launches and the upcoming CEO strategy update, while risks include clinical trial setbacks, competitive pressures, and integration of potential acquisitions like Nuvalent.

INMD trades at $15.36, up 2.92% today, with a bullish technical signal from moving averages. The company maintains strong profitability with a 77.84% gross margin and 23.27% net margin, while valuation ratios appear attractive with a P/E of 11.32. Recent news includes an unsolicited acquisition offer of $16.75 per share from Steel Partners and Q2 2026 revenue guidance of $95.2M-$95.4M.

The stock presents a mixed outlook: upside exists from potential acquisition interest and solid fundamentals, but risks include a recent earnings miss, ongoing securities fraud investigations, and overbought technical indicators. Analyst consensus is divided with a $16.50 price target suggesting moderate upside from current levels.